Literature DB >> 22459003

Cytomegalovirus-specific T-cell immunity to assign the infection status in individuals with passive immunity: a proof of principle.

Tina Schmidt1, Marion Ritter, Jan Dirks, Barbara C Gärtner, Urban Sester, Martina Sester.   

Abstract

BACKGROUND: Serological analysis of the infection status with the human cytomegalovirus (CMV) may be inaccurate after transfusion of blood products due to the variable content of CMV-specific antibodies.
OBJECTIVES: In this situation, analysis of cellular immunity may represent a more accurate parameter to assign the individual CMV-infection status. This hypothesis was assessed in a sequence of clinically defined events where a CMV-seronegative patient received human immunoglobulins before AB0 incompatible transplantation of a graft from his CMV-seropositive mother and developed CMV-primary infection thereafter. STUDY
DESIGN: Humoral immunity was analyzed using ELISA, and CMV-specific CD4 T-cells were flow-cytometrically quantified using intracellular cytokine staining after a 6 h-stimulation with a CMV-antigen lysate.
RESULTS: Prior to transplantation, both CMV-specific antibody-titers and T-cell frequencies were below detection limit. After plasma infusion, the patient was temporarily seropositive but remained T-cell negative indicating passive immunity. CMV-specific T-cells became stably detectable after graft-related primary infection, thereby confirming a truly positive infection status.
CONCLUSION: This case provides an instructive proof of principle to show that CMV-specific CD4 T-cells may serve as an accurate marker to define the true CMV-infection status in situations where serological testing is limited by the presence of passively administered antibodies.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22459003     DOI: 10.1016/j.jcv.2012.03.001

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  5 in total

Review 1.  Utility of Cytomegalovirus Cell-Mediated Immunity Assays in Solid Organ Transplantation.

Authors:  Victoria G Hall; Atul Humar; Deepali Kumar
Journal:  J Clin Microbiol       Date:  2022-05-11       Impact factor: 11.677

2.  Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.

Authors:  Davide Abate; Alda Saldan; Carlo Mengoli; Marta Fiscon; Cristina Silvestre; Loredana Fallico; Marta Peracchi; Lucrezia Furian; Riccardo Cusinato; Luciana Bonfante; Barbara Rossi; Francesco Marchini; Dino Sgarabotto; Paolo Rigotti; Giorgio Palù
Journal:  J Clin Microbiol       Date:  2013-05-15       Impact factor: 5.948

3.  An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.

Authors:  Sascha Barabas; Theresa Spindler; Richard Kiener; Charlotte Tonar; Tamara Lugner; Julia Batzilla; Hanna Bendfeldt; Anne Rascle; Benedikt Asbach; Ralf Wagner; Ludwig Deml
Journal:  BMC Immunol       Date:  2017-03-07       Impact factor: 3.615

Review 4.  Virus-specific T cells in pediatric renal transplantation.

Authors:  Thurid Ahlenstiel-Grunow; Lars Pape
Journal:  Pediatr Nephrol       Date:  2020-03-27       Impact factor: 3.714

5.  Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.

Authors:  Elena Rho; Bettina Näf; Thomas F Müller; Rudolf P Wüthrich; Thomas Schachter; Seraina von Moos
Journal:  Clin Transplant       Date:  2021-10-28       Impact factor: 3.456

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.